Level C· Early human research exploring benefitsProspective StudyPubMed

Lysophosphatidylcholine-induced aberrant adipogenesis in mesenchymal stem cells and impaired antibacterial function in adipocytes of creeping fat.

Wu F., Xie W., Yu A., Lin X., Ouyang T., Fei J.

Prospective Study on Autoimmune Research, published in J Crohns Colitis (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Crohns Colitis (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
39888411
DOI
10.1093/ecco-jcc/jjaf019

Abstract (original English)

Creeping fat (CF) in Crohn's disease (CD) is characterized by hyperplastic mesenteric adipose tissue (MAT) encasing fibrotic intestinal segments. Creeping fat exhibits disruptions in microbiota and lipid metabolism, particularly in lysophosphatidylcholine (LPC). This study aims to elucidate the impact of LPC on adipogenic differentiation of mesenchymal stem cells in CF and its effects on immune defense functions in the differentiated adipocytes. Isolated adipocytes of MAT from CD and non-CD patients were analyzed for bacterial counts and composition using AQ-PCR and 16S rRNA. RNA sequencing was performed on isolated adipocytes to assess functionality. Lysophosphatidylcholine levels in CD patients and their effects on adipocyte immune defense were measured using lipidomics, ELISA, and bacterial killing assays. A trinitrobenzenesulfonic acid (TNBS)-induced colitis model was used to measure LPC levels in plasma and gene expression in MAT. Significant shifts in microbial diversity and bacterial load were observed in CF-derived adipocytes, characterized by increased colonization by pathogenic bacteria and diminished antibacterial capabilities. Sequencing analysis revealed downregulation of antibacterial genes, including SAA1/2, and upregulation of lipid metabolism-related genes. Lipidomic analysis of CF showed elevated LPC levels, a pro-inflammatory lipid also found in plasma of CD

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
LysophosphatidylcholinesMesenchymal Stem CellsAdipogenesisAdipocytesHumansAnimalsMiceCrohn DiseaseMaleFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research